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Abstract 
This study compared the efficacy of two protocols for oral care using either 
chlorhexidine or benzydamine as oral rinses to alleviate mucositis in children 
undergoing chemotherapy. Eligible participants were randomised to receive either 
protocol for 3 weeks in a two-period crossover design. The occurrence of ulcerative 
lesions and severity of mucositis were measured at baseline and twice weekly, using 
the modified Oral Assessment Guide (OAG). Data were continuously analysed by 
plotting them directly on predefined sequential charts. According to this sequential 
analysis, the study could be terminated at the 34th within subject comparison, with a 
statistically significant reduction in ulcerative lesions (P<0.05) and severity of 
mucositis (P<0.05) in children on the chlorhexidine protocol. These findings suggest 
that chlorhexidine together with oral care might be helpful in alleviating mucositis 
when given prophylactically to children on chemotherapy, but the therapeutic benefit 
needs to be confirmed in a larger trial 
 
1. Introduction 
Oral mucositis is one of the most debilitating complications following chemotherapy, 
occurring in approximately 52–80% of children with cancer so treated [1, 2 and 3]. 
Despite this high prevalence, there have been few studies published on reducing the 
incidence and severity of oral mucositis in children. Oral mucositis remains an 
unresolved clinical problem for experience oncological teams treating children with 
chemotherapy. 
 
Oral mucositis normally lasts for 3 weeks, beginning at 3–5 days and peaking at 7–14 
days after chemotherapy [4]. The probable mechanisms involve complex biological 
events mediated by a number of inflammatory cytokines, the direct effect of the 
chemotherapeutic drug or irradiation on the basal epithelium and connective tissue, 
and the oral microbial environment [5]. Several therapy- and patient-specific factors, 
including the chemotherapeutic drug itself, the type of malignancy, age, neutrophil 
count, and level of oral care, are thought to be important in the aetiology of oral 
mucositis. To a large extent, the severity of the condition is related to the specific 
chemotherapeutic agents used: methotrexate, fluorouracil (5-FU), doxorubicin 
(Adriamycin) and etoposide (VP-16) are particularly stomatotoxic [6 and 7]. 
 
Clinically, oral mucositis presents with an initial mucosal erythema, which often 
progresses to patchy mucositis, and then extensive ulceration and desquamation [8 
and 9]. Although it is not a life-threatening complication, its impact in clinical 
practice is great, and it may have wide-ranging physical and psychosocial 
implications for patients. The ulcerative lesions are often very painful, requiring 
treatment with analgesics and supportive nutrition, and the cancer treatment may need 
to be interrupted or modified. In myelosuppressed individuals, the ulcerative lesions 
can even predispose to potentially fatal bacteraemia. All these conditions may 
increase treatment costs, preclude further treatment, jeopardise survival, or 
irrevocably alter the quality of life of the patient [10 and 11]. 
 
Although oral mucositis has been studied for many years, no one strategy or approach 
has proved to be reliably effective. For nearly all of the existing approaches, the 
outcomes for children remain unknown. In 1989, a consensus conference on oral 
complications sponsored by the National Institutes of Health concluded that no 
currently available drug could effectively prevent or treat oral mucositis [12]. Two 
recent reviews conducted by the Cochrane Oral Health Group [13] and the Joanna 
Briggs Institutes [14] identified only that the application of ice chips might possibly 
prevent bolus fluorouracil-induced mucositis, with few other recommendations for 
oral mucositis in general. The efficacy of several bioactive factors and 
immunomodulatory therapy in controlling oral mucositis is now under investigation 
[15 and 16]. Although these specific therapies may provide new insights into the 
management of this condition, they are costly, which may limit their widespread 
application. Given the low cost and simplicity of routine oral care, oral hygiene 
protocols should be the standard intervention, with specific therapies to be developed 
in addition [17]. In fact, as the role of oral microflora in the pathogenesis of mucositis 
becomes increasingly clear, so too does the concept of enhanced oral hygiene in the 
management of mucositis [5]. 
 
Controversies and confusions persist on the different measures to be included in 
protocols of oral care. The Bass method of tooth-brushing and the frequent use of 
normal saline are generally recommended for individuals undergoing cancer therapy 
[1 and 18]. Although the use of chlorhexidine in oral mucositis has been widely 
examined, the results have varied. In fact, the studies on chlorhexidine are difficult to 
interpret and compare because of differences in the underlying disease, the chosen 
cancer therapy, the patient's age and the rinse schedules. As chlorhexidine has been 
shown to reduce oral bacterial and fungal colonisation, some studies support its 
prophylactic use in patients receiving myelosuppressive therapy [8 and 19]. 
Benzydamine is a non-steroidal drug with anti-inflammatory, anaesthetic and 
antimicrobial properties [20]. It has been suggested that it may be more effective 
when used prophylactically to ‘prevent’ mucositis rather than therapeutically once 
mucositis is present [21]. Studies on patients receiving irradiation for head-and-neck 
malignancy have revealed a statistically significant reduction in oral ulceration in 
patients using benzydamine prophylactically [21 and 22]. No studies have been traced 
comparing the effects of chlorhexidine and benzydamine rinses in chemotherapy-
induced oral mucositis, in particular for patients with childhood cancer. Our aim was 
therefore to compare the efficacy of two protocols differing in the type of oral rinse, 
0.2% w/v chlorhexidine gluconate versus 0.15% w/v benzydamine hydrochloride, in 
alleviating oral mucositis in children undergoing chemotherapy. 
 
2. Patients and methods 
2.1. Setting and sample 
The study was conducted in a children's cancer centre in a university-affiliated 
hospital in Hong Kong after approval from the ethics committee. Children between 
the ages of 6 and 17 years who had received two consecutive cycles of high-dose or 
combination chemotherapy for haematological malignancies or solid tumours were 
enrolled in the study. The children were capable of tooth-brushing and mouth-rinsing 
as judged by the investigators. The study was conducted in accordance with the 
pertinent sections of the Declaration of Helsinki; all the children gave their assent to 
participate and their parents provided written informed consent before enrolling in the 
study. 
 
2.2. Study design 
This was a prospective, randomised, non-blinded, two-period crossover study with 
continuous sequential analysis. This design was based on the fact that it is extremely 
difficult to control for all therapy- and patient-specific variables in a single-centre 
study, and on the practical difficulty of obtaining a sufficient number of participants, 
given the low incidence of childhood cancer. In addition, the distinguishable colour 
and taste of chlorhexidine and benzydamine oral rinses meant that blinding was not 
considered feasible. Eligible participants were randomly assigned to receive either 
protocol of oral care with chlorhexidine or benzydamine on the initial chemotherapy 
cycle, and then crossed over at the subsequent cycle (Fig. 1). There would be a period 
of 1–2 weeks’ ‘washout’ between the two chemotherapy cycles, depending on the 
treatment protocol. Randomisation was balanced for every four subjects and stratified 
on the type of chemotherapeutic agent.  
 
Figure 1 here 
 
It is not the usual practice in the institution where the study was conducted to have 
standard oral care and routine dental examinations before commencing chemotherapy. 
For the purpose of this study, participants were instructed to maintain strict oral 
hygiene according to the protocol on the first day of chemotherapy and to continue for 
the 3 weeks of each study period. The protocol included (a) tooth-brushing using the 
Bass method and mouth-rinsing with either of the allocated rinses in the early 
morning and at bedtime; (b) normal saline rinsing within 30 min of meals; (c) normal 
saline rinsing every 4 h in the first and third week, and every 2 h in the second week 
after chemotherapy. Participants were instructed to rinse their mouths using a 
ballooning and sucking motion of the cheeks for 30 s without swallowing. Those who 
complained of stinging or burning were advised to dilute the oral rinses with an equal 
volume of normal saline (1:1) [20 and 23]. Special attention was given to maintaining 
the integrity of the protocol throughout the study, which included pretreatment 
instruction on oral care, reinforcement practice sessions every week and a cartoon-
illustrated reminder. Each participant was given a practice diary; compliance was 
continuously monitored by assessing the frequency of oral care recorded in the diary, 
and was counterchecked by determining the amount of rinse used and left in returned 
bottles. Both the child and parent were also interviewed at each assessment visit about 
the performance of oral care on the preceding day. The calculation of compliance was 
based mainly on the diary data, from which the average percentage of oral care 
performed each day (from 07:00 to 23:00) during the study period was computed as 
the sum of the percentage of oral care performed every day divided by 21. The level 
of oral care considered adequate was set at 80%. 
 
The outcome variables, including the occurrence of ulcerative lesions and severity of 
oral mucositis, were measured at baseline and twice a week by one of the 
investigators and an oncology nurse. Both of them had received training on using the 
chosen scoring system. Ramirez-Amador and colleagues suggest that two time points 
per week for assessment are sufficient to obtain estimates of oral mucositis and to 
ensure that oral ulcerative lesions are not missed [9]. A frequency of twice a week 
also minimises the burden on the participant. More frequent assessment was not 
otherwise possible as patients were often discharged after chemotherapy and so the 
analysis would have been complicated by large amounts of missing data. 
 
The Oral Assessment Guide (OAG) designed by Eilers and associates [24], which has 
been used in different cancer treatments, was used for the purposes of this study. The 
OAG is applicable in children because of its simplicity and the limited number of 
items, requiring only 3–4 min to complete. Nevertheless, in order to create a more 
accurate reflection of the severity of oral mucositis, we made the following minor 
modifications to the OAG, as detailed in Table 1, with the agreement of oncology 
researchers and specialists. The item ‘mucous membrane’ was divided into 
buccal/palatal and labial mucous membranes, as most oral lesions are located in the 
labial and buccal mucosa. The item ‘teeth/denture’ was deleted, as it does not relate 
directly to the degree of tissue damage and change. Eight items were assessed and a 
score of 1 (normal) to 3 (severely affected) was assigned to each. Individual scores 
were added to produce a mucositis score with a range of 8–24. Interrater reliability for 
the modified OAG was established using three nurses who completed four oral 
assessments on children undergoing chemotherapy, with a Kappa coefficient equal to 
0.81–0.94. For construct validity, the modified scale was tested prospectively with the 
same group of children. The pattern of oral mucositis scores followed the clinical 
condition of the mouth, with increasing scores as the lesions worsened followed by 
decreasing scores as they healed.  
 
Table 1 here 
 
2.3. Data analysis 
Sequential analysis was the chosen method of statistical analysis on outcome 
variables, in which the presence of any statistical differences in responses was 
determined after each within-subject comparison. Such analysis is based on the 
premise that accumulating data can be monitored and analysed continuously, and any 
decision to stop the trial can be applied immediately. The total number of participants 
entering the study is therefore not predetermined. The statistical techniques of 
sequential analysis take into account the effect of increasing the chance of type I error 
by repeated examination of the accumulating data, so valid interpretations can be 
made after each within-subject comparison in a crossover trial [25, 26 and 27]. 
 
A closed sequential-analysis chart with the boundaries set to give a two-sided 
significance of 0.05 and a power of 90% for the probability of detecting a critical 
value of 0.75 was used to compare the effects of chlorhexidine and benzydamine on 
ulcerative lesions [25] ( Fig. 2). With sequential analysis, a preference for 
chlorhexidine was plotted (by dots) toward the upper boundary if ulcerative lesions 
occurred in a participant when using benzydamine, but not chlorhexidine. Conversely, 
a preference for benzydamine was plotted (by dots) toward the lower boundary if 
ulcerative lesions occurred when using chlorhexidine, but not benzydamine. If the 
outcomes for ulcerative lesions were the same, the case would be excluded from 
plotting on this sequential-analysis chart.  
 
Figure 2 here 
 
Another closed, sequential, t-test analysis chart with the boundaries set to detect a 
critical difference of 0.6 of a standard deviation with a two-sided significance of 0.05 
and a power of 90% was used to examine the differences between chlorhexidine and 
benzydamine in relation to the severity of oral mucositis [25] ( Fig. 3). The area under 
the curve (AUC) of a severity–time curve, from days 1 to 21, was used to summarise 
the severity of oral mucositis in individual participants before any sequential analysis. 
The use of the AUC is considered clinically relevant and statistically valid to the 
analysis of serial data [28]. With sequential analysis, the sum of the differences in the 
mean AUC between each within-subject measurement was squared and divided by the 
square of the sum of the differences in mean AUC, so computing a Z value (Z=(sum 
d)2/sum d2). The sequential-analysis chart plotted the Z values (by dot) against the 
number of within-subject comparisons until one of the boundaries was crossed.  
 
Figure 3 here 
 
3. Results 
3.1. Study population 
Between April 2000 and April 2001, a total of 40 children were enrolled and 
randomly allocated to receive one of the oral care protocols. 34 participants 
completed the two protocols for the full period (6 weeks) to enter the sequential 
analyses, 17 in each protocol. 6 participants were excluded because they were not able 
to complete the two protocols, either because cancer treatment was withdrawn or they 
went for a bone marrow transplant (Table 2). As the trial design was crossover rather 
than parallel, an intention-to-treat analysis after the first oral-care protocol was not 
considered possible.  
 
Table 2 
 
34 participants were thus included in the sequential analyses; 21 boys and 13 girls, 
ranging in age from 6 to 16 years (mean 10.3 years (standard deviation (S.D.) 3.3). 
Their years of schooling ranged from 0 to 11 years (mean 4.5 (S.D. 3)). Before the 
study, 16 participants (47%) attested to performing oral care in the form of tooth-
brushing twice a day. The most common diagnosis was acute lymphoblastic 
leukaemia (ALL) (56%). The more commonly used chemotherapy regimens included 
vincristine/doxorubicin (32%), methotrexate (24%) and vincristine/methotrexate 
(15%). 16 participants (47%) had received chemotherapy previously, with mild to 
moderate mucositis being reported. Baseline measurements of oral mucosal and 
myelosuppression status, as well as renal function profiles, were similar and there 
were no statistically significant differences in these measures before the start of each 
chemotherapy cycle. 
 
3.2. Carry-over effect 
The overall mean AUC for oral mucositis throughout the study was 8.7 (S.D. 4.7) for 
patients who received chlorhexidine first, and 6.5 (S.D. 5.1) for those who received 
benzydamine first. There was no statistically significant difference in the patients’ 
mean AUC for oral mucositis according to the order in which the protocols were 
received (t=1.31, P>0.05), indicating there was no carry-over effect from the initial 
oral-care protocol. 
 
3.3. Ulcerative lesions 
In this study, 27 and 59% of participants developed ulcerative lesions when receiving 
the protocols with chlorhexidine and benzydamine, respectively. Most of the 
ulcerative lesions were located in the buccal mucosa (62%) and labial mucosa (35%). 
One-third of participants (38%) with haematological malignancies, and more than half 
of those (55%) with solid tumours, developed ulcerative lesions during chemotherapy 
(Table 3). Approximately half of all ulcerative lesions occurred in those receiving 
methotrexate infusions. In Fig. 2, a line is plotted showing the sum of the preferences; 
it crosses the upper boundary at the 15th preference among the 34 within-subject 
comparisons, indicating that the use of the chlorhexidine significantly decreased the 
manifestation of ulcerative lesions compared with benzydamine (P<0.05). 
 
Table 3 
 
3.4. Oral mucositis 
Oral mucositis appeared around day 3, peaked on day 10 and started to resolve by day 
14 after chemotherapy (Fig. 4). The OAG scores for mucositis in patients who used 
chlorhexidine from days 1 to 21 ranged from 8 to 13 (mean 8.6–9.5; S.D. 0.9–1.5). 
When using benzydamine patients had higher OAG scores for mucositis (8–18; mean 
8.7–10.3, S.D. 0.8–2.2). The AUC for mucositis in patients using chlorhexidine 
ranged from 0 to 17.5 (mean 6.1, S.D. 4.6). When using benzydamine, patients had a 
higher range of AUC for mucositis (0–26; mean 8.7, S.D. 6.6). As shown in Fig. 3, a 
cumulative plot of the AUC was made for each within-subject comparison, and when 
statistical significance (P<0.05) was reached after the 34th comparison this allowed 
the conclusion that the use of the chlorhexidine significantly reduced the severity of 
mucositis compared with benzydamine. 
 
Figure 4 here 
 
3.5. Compliance with oral care 
Overall, the children using both protocols achieved acceptable compliance (>80%) 
throughout the 6-week study period. The mean compliance for protocols containing 
chlorhexidine and benzydamine was 92.6% (S.D. 5.3) and 93.2% (S.D. 5.8), 
respectively. 
 
4. Discussion 
Studies comparing oral rinses are few and those reported have mainly been in adult 
populations. Our findings indicate a significantly lower incidence and severity of oral 
mucositis in patients on the protocol with chlorhexidine than with benzydamine. The 
present data support the findings of earlier, non-randomised studies on chlorhexidine 
in the prophylaxis of chemotherapy-induced mucositis in children [29 and 30]. 
However, they contrast with the data of Samaranayake and colleagues, who found no 
significant difference in irradiation-induced mucositis in patients with head-and-neck 
cancer receiving chlorhexidine and benzydamine twice daily [31]. This discrepancy 
may be due to the small number of patients in Samaranayake's study, which would 
have reduced the power to detect significant findings. A large, randomised, controlled 
trial conducted by Dodd and colleagues comparing 222 adult outpatients using either 
chlorhexidine or water showed that chlorhexidine was not beneficial [32]. In Dodd's 
study, mucositis was assessed monthly, a method that might be too insensitive to 
detect mucosal changes and thus a significant proportion of mucositis may have 
remained undetected in their study. Furthermore, most of their patients were receiving 
adjuvant chemotherapy for breast and lung cancers, which is not highly stomatotoxic, 
whereas highly stomatotoxic agents with dose intensification were used in our 
investigation. High-dose methotrexate is frequently used in the treatment of children 
with ALL and osteosarcoma. Oral mucositis is a major toxicity associated with 
methotrexate [6, 7 and 33]. The incidence of ulcerative mucositis was close to 52% 
for the methotrexate infusions in our study, similar to that found by previous 
investigators [33]. Nevertheless, it is rather remarkable to find a higher incidence of 
ulcerative mucositis in a paediatric group with solid tumours than in a group with 
haematological malignancies. Childers and colleagues also reported similar findings, 
and suggested that these relate to the use of more dose intensification and 
combination chemotherapeutic regimens in treating childhood solid tumours in recent 
years [2]. 
 
Some findings suggest that the frequency and consistency of oral care are more 
important in reducing oral mucosal damage associated with cancer treatment than the 
particular agent used [18 and 32]. In the current study, the lack of a control or 
comparison group with a normal saline and tooth-brushing regimen did not allow us 
to discern whether the clinical benefits of the protocol were due solely to the 
chlorhexidine or to the effect of the systematic performance of oral care. 
Nevertheless, it can be speculated from the data presented here that chlorhexidine 
may play a part in reducing oral mucosal damage during chemotherapy, possibly 
through plaque control and a reduction in the oral microflora. Dahllof and colleagues, 
examining the oral condition of children treated by bone marrow transplantation, 
found that those patients with no oral plaque who received cancer chemotherapy 
developed significantly less and a shorter period of mucositis [34]. A study of 
children with acute leukaemia being treated with chemotherapy showed that 
chlorhexidine significantly decreased the counts of total aerobes and streptococci 
[35]. Although benzydamine reportedly has antimicrobial properties [20, 21 and 22], 
its bland antiseptic effects in suppressing the oral microflora are unclear. In 
Samaranayake's study, neither chlorhexidine nor benzydamine was found to be 
effective in controlling the oral carriage of coliforms and Staphylococcus aureus [31]. 
Quantitative baseline and posttreatment analyses of selected components of the oral 
microflora are required to validate the efficacy of chlorhexidine and benzydamine in 
microbial suppression during chemotherapy. In the present study, the 59% prevalence 
of ulcerative mucositis in children using benzydamine is considerably less than the 
reported approximately 80% in previous studies [1 and 3], suggesting that 
benzydamine may have some effects on mucositis. It has been speculated that the 
anti-inflammatory capacity of benzydamine resulting from its ability to suppress 
proinflammatory cytokine production may reduce cancer treatment-induced mucosal 
toxicity [36]. In a recent multicentre study, benzydamine applied 4–8 times daily 
before and during radiotherapy was effective in the prophylactic treatment of 
radiation-induced mucositis [37]. In Epstein's study, the frequency of application of 
benzydamine was 2–4 times higher than in the present investigation. Therefore, we 
think that the frequency and duration of benzydamine application might together 
affect its efficacy. It is likely that children might not receive the maximum benefit 
from benzydamine by twice-daily rinsing. For this reason, further studies to determine 
which factors modulate benzydamine's efficacy and the optimal frequency of 
benzydamine rinses are warranted. 
 
Mouthwash-induced discomfort and variable patient tolerance have been reported in 
some studies of chlorhexidine and benzydamine rinses [31 and 38]. In this study, the 
children surprisingly had accepted and tolerated both the oral rinses well, and the 
level of adherence to the oral care regimen was high. Although some children 
experienced an initial stinging, dilution with normal saline alleviated this sufficiently 
to allow the children to continue with the study protocol. In agreement with 
observations by Lang and co-workers, a 0.2% chlorhexidine rinse is considered 
acceptable to children [39]. This conclusion is also supported by O'Sullivan and 
colleagues, who reported 100% compliance in children who had received prophylactic 
0.2% chlorhexidine rinses four times a day for the entire duration of the study [35]. 
 
In conclusion, chlorhexidine complementing an oral care protocol offers some 
promise in reducing oral mucositis for children undergoing chemotherapy. However, 
our findings must be interpreted with caution because the inability to establish a 
blinded design could influence the reliability and validity of the outcome measures. In 
addition, the fact that the study was relatively small limits the ability to generalise 
from the data, so more comprehensive evaluations, including psychosocial outcomes 
with larger population groups, are required to confirm our findings. As the low 
incidence of childhood cancer and the wide range in ages pose methodological 
problems, multi-institutional collaborative research is needed in order to define 
further the optimal regimen for oral care in children and provide the basis for best 
practice in relation to oral mucositis.  
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Figures and Tables: 
 
Fig. 1. Flow chart of the progress of patients through the trial. 
 
 
 
 
 
 
Table 1. Oral assessment guide (OAG) 
 
 
 
 
 
 
 Fig. 2. Sequential-analysis chart for within-subject comparisons on ulcerative lesion manifestation. L, 
lower boundary; M, middle boundary; U, upper boundary.  
 
 
 
 
 
 
 
Fig. 3. Sequential t-test analysis chart for within-subject comparison on AUC values 
for oral mucositis. AUC, area under the curve; M, middle boundary; U, upper 
boundary 
 
 
 
 
 
 
 
 
 
 
Table 2. Demographic and clinical characteristics of participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Malignancies and frequency of chemotherapy infusions affected with oral ulcers 
 
 
